Q4 2025 Precigen Inc Earnings Call Transcript
Key Points
- Precigen Inc (PGEN) successfully transitioned from an R&D company to a revenue-generating commercial biotech company with the launch of PAPZIMEOS.
- PAPZIMEOS received full FDA approval with a broad label for adult RRP, reflecting its unmatched efficacy and strong clinical data.
- The company reported strong revenue growth, with Q4 2025 net product revenue at $3.4 million and expected Q1 2026 revenue to exceed $18 million.
- Payer coverage for PAPZIMEOS has expanded significantly, now covering approximately 215 million lives, including major commercial, Medicare, and Medicaid payers.
- Precigen Inc (PGEN) is actively pursuing geographic expansion, with a marketing authorization application submitted to the EMA for PAPZIMEOS.
- Precigen Inc (PGEN) reported a net loss attributable to common shareholders of $429.6 million for the year ended December 31, 2025.
- Selling, general, and administrative expenses increased by $28.8 million, primarily due to costs related to PAPZIMEOS' commercial activities.
- The company does not plan to provide regular forward-looking revenue projections, which may limit investor visibility into future financial performance.
- There is a reliance on the successful conversion of patients from the support hub to receiving reimbursed treatment, which can vary by institution.
- The company faces challenges in ensuring the activation of institutional networks and payer coverage to facilitate patient treatment.
Good afternoon, ladies and gentlemen, and welcome to the Precigen full-year 2025 financial results and business update conference call. (Operator Instructions) This call is recorded on Wednesday, March 25, 2026.
I would now like to turn the conference over to Steve Harasym. Please go ahead.
Thank you, operator, and thank you to all those joining us for our fourth-quarter and year-end 2025 update call. Joining me today are Helen Sabzevari, our President and CEO; Phil Tennant, our Chief Commercial Officer; and Harry Thomasian, our CFO.
Before we begin our prepared remarks, I remind everyone that we will be making certain forward-looking statements. These statements are based on our current expectations and beliefs. We encourage you to review the slide in the presentation and in our SEC filings, which include risks and uncertainties that could cause actual results to differ from today's forward-looking statements.
With that, I will now turn the call over to Helen.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
